Related Experiment Video
Updated: May 27, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
CDC25 phosphatase inhibitors: an update
A Lavecchia1, C Di Giovanni, E Novellino
1Dipartimento di Chimica Farmaceutica e Tossicologica, "Drug Discovery" Laboratory, Universita di Napoli "Federico II", Napoli, Italy. lavecchi@unina.it
Mini Reviews in Medicinal Chemistry
|November 11, 2011
Summary
The cell division cycle 25 (CDC25) protein family regulates cell division and DNA damage response. Inhibiting CDC25 phosphatases is a promising cancer therapy strategy, with recent advancements in inhibitor design.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The cell division cycle 25 (CDC25) family are conserved dual-specificity phosphatases.
- They are critical regulators of cell cycle progression and DNA damage response.
- CDC25 dysregulation is implicated in various cancers, correlating with poor prognosis.
Purpose of the Study:
- To review recent developments in CDC25 phosphatase inhibitor design.
- To highlight CDC25 proteins as attractive therapeutic targets in oncology.
Main Methods:
- Literature review of patents and publications since 2008.
- Analysis of recent advancements in the design of CDC25 inhibitors.
Main Results:
- CDC25 phosphatases are key regulators of cell cycle transitions via CdK/cyclin activation.
- Abnormal CDC25 expression is linked to malignant transformation and poor clinical outcomes.
- Inhibition of CDC25 proteins is a validated therapeutic strategy in oncology.
Conclusions:
- CDC25 phosphatase inhibitors represent a significant area of research in cancer therapy.
- Continued development in inhibitor design is crucial for effective oncology treatments.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
02:54Protein Kinases and Phosphatases
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...